Onconetix, Inc. Share-based Payment Arrangement, Expense
Onconetix, Inc. (ONCO) reported Share-based Payment Arrangement, Expense of $7.36 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-13
- Onconetix, Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $7.36K, a 76.25% decline year-over-year.
- Onconetix, Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $22.30K, a 23.76% decline year-over-year.
- Onconetix, Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $4.23K, a 98.76% decline year-over-year.
- Onconetix, Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $9.79K, a 78.54% decline year-over-year.
- Onconetix, Inc. share-based payment arrangement, expense for fiscal 2025 was $74.27K, a 83.07% decline from fiscal 2024.
- Onconetix, Inc. share-based payment arrangement, expense for fiscal 2024 was $438.65K, a 33.02% increase from fiscal 2023.
- Onconetix, Inc. share-based payment arrangement, expense for fiscal 2023 was $329.76K, a 83.30% decline from fiscal 2022.
- Onconetix, Inc. share-based payment arrangement, expense for fiscal 2022 was $1.97M.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 9 month as first filed | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $7.36K 10-Q · filed 2026-08-13 | $29.66K 10-Q · filed 2026-08-13 | $33.90K derived: sum of 3 quarters · filed 2026-08-13 | $43.69K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $22.30K 10-Q · filed 2026-05-13 | $26.54K derived: sum of 2 quarters · filed 2026-05-13 | $36.33K derived: sum of 3 quarters · filed 2026-05-13 | $67.32K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $4.23K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $14.03K derived: sum of 2 quarters · filed 2026-03-13 | $45.01K derived: sum of 3 quarters · filed 2026-08-13 | $74.27K 10-K · filed 2026-03-13 | ||||
| 2025-09-30 | $9.79K 10-Q · filed 2025-11-13 | $40.78K derived: sum of 2 quarters · filed 2026-08-13 | $70.03K 10-Q · filed 2025-11-13 | $411.18K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $30.98K 10-Q · filed 2026-08-13 | $60.24K 10-Q · filed 2026-08-13 | $401.38K derived: sum of 3 quarters · filed 2026-08-13 | $447.02K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $29.26K 10-Q · filed 2026-05-13 | $370.40K derived: sum of 2 quarters · filed 2026-05-13 | $416.03K derived: sum of 3 quarters · filed 2026-05-13 | $415.26K derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $341.14K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $386.78K derived: sum of 2 quarters · filed 2026-03-13 | $386.00K derived: sum of 3 quarters · filed 2026-03-13 | $438.65K 10-K · filed 2026-03-13 | ||||
| 2024-09-30 | $45.63K 10-Q · filed 2025-11-13 | $44.86K derived: sum of 2 quarters · filed 2025-11-13 | $97.51K 10-Q · filed 2025-11-13 | -$136.49K derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$775.00 10-Q · filed 2025-08-14 | $51.88K 10-Q · filed 2025-08-14 | -$182.13K derived: sum of 3 quarters · filed 2025-08-14 | -$76.72K derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | $52.65K 10-Q · filed 2025-06-12 | -$181.35K derived: sum of 2 quarters · filed 2025-06-12 | -$75.95K derived: sum of 3 quarters · filed 2025-06-12 | $196.83K derived: sum of 4 quarters · filed 2025-06-12 | ||||
| 2023-12-31 | -$234.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-02 | -$128.60K derived: sum of 2 quarters · filed 2025-06-02 | $144.18K derived: sum of 3 quarters · filed 2025-06-02 | $329.76K 10-K · filed 2025-06-02 | ||||
| 2023-09-30 | $105.40K 10-Q · filed 2024-12-10 | $378.18K derived: sum of 2 quarters · filed 2024-12-10 | $563.76K 10-Q · filed 2024-12-10 | $394.00K 10-Q · filed 2023-11-17 | $1.54M derived: sum of 4 quarters · filed 2024-12-10 | |||
| 2023-06-30 | $272.78K 10-Q · filed 2024-08-29 | $458.36K 10-Q · filed 2024-08-29 | $538.00K 10-Q · filed 2023-10-20 | $1.43M derived: sum of 3 quarters · filed 2024-08-29 | $1.33M derived: sum of 4 quarters · filed 2024-08-29 | |||
| 2023-03-31 | $185.58K 10-Q · filed 2024-05-20 | $659.00K 10-Q · filed 2023-05-12 | $1.16M derived: sum of 2 quarters · filed 2024-05-20 | $1.06M derived: sum of 3 quarters · filed 2024-05-20 | ||||
| 2022-12-31 | $974.57K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-11 | $874.57K derived: sum of 2 quarters · filed 2024-04-11 | $1.97M 10-K · filed 2024-04-11 | $700.00K 10-K · filed 2023-03-09 | ||||
| 2022-09-30 | -$100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $1.00M 10-Q · filed 2022-11-14 | ||||||
| 2022-06-30 | $1.10M 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |